A A A

Institute News

Seminar on T-cell receptor-mediated decision making

Dr John James will be speaking on Exploring the mechanism of T-cell receptor-mediated decision making: how does a receptor count to ten? as part of the Institute's seminar series, on 24 April. More...

PI3K enzymes in immmune activation: forthcoming seminar, 10 April

Dr Klaus Okkenhaug has a long-standing interest in the roles of phosphoinositide 3-kinase (PI3K) enzyme isoforms in immune activation, particularly in T and B cells. His research group is based at the Laboratory of Lymphocyte Signalling and Development at the Babraham Institute and he currently holds a Wellcome Trust New Investigator Award. More...

The latest trials and other clinical studies approved to take place via the Institute of Immunity and Transplantation:

Clinical trials and other patient-related studies

Pulmonary arterial hypertension cohort study

National Cohort study of Idiopathic and Heritable Pulmonary Arterial Hypertension.
More...

Cardiovascular disease and TGF-beta superfamily

Isolation and characterisation of blood-derived progenitor cells in patients with cardiovascular disease and TGF-beta superfamily related diseases (Progenitor Study).
More...

Gastro-oesophageal reflux in scleroderma

Investigation into the role of gastro-oesophageal reflux  in Pulmonary Fibrosis in Scleroderma (GER Study).
More...

Zibotentan in scleroderma

A phase II, single centre, randomised, placebo controlled, 3-part trial to assess the safety, tolerability and efficacy of Zibotentan in patients with renal disease secondary to scleroderma. ( Zebra)
More...

Adalimumab in rheumatoid arthritis

A post marketing observational study (PMOS) to determine the effectiveness and patient satisfaction with Adalimumab treatment in patients with rheumatoid arthritis (OPERA study).
More...

Selexipag in pulmonary arterial hypertension

Long-term single-arm open-label study, to assess the safety and tolerability of selexipag (ACT-293987) in patients with pulmonary arterial hypertension (Griphon Open label) .
More...

Severe rheumatoid arthritis

Open-label, Phase IIIb study to evaluate the efficacy and safety of subcutaneous (SC) Tocilizumab monotherapy or combination therapy with methotrexate (MTX) or other non-biologic disease modifying anti-rheumatic drugs (DMARDs) in patients with severe Rheumatoid Arthritis (RA) who are being treated with an anti-tumour necrosis factor (anti-TNF) agent and that have not achieved an adequate response to treatment. More...

Adalimumab in spondyloarthritis

A multi-centre, randomized, double-blind, study comparing the efficacy and safety of continuing versus withdrawing Adalimumab Therapy in maintaining remission in subjects with non-radiographic axial spondyloarthritis. More...

Page last modified on 06 feb 14 12:27